| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/08/2005 | CA2445743A1 Methods for modulating neuronal responses |
| 04/07/2005 | WO2005031341A2 Methods for predicting development of insulin resistance |
| 04/07/2005 | WO2005031000A2 Treating neuropathic pain with neuropeptide ff receptor 2 agonists |
| 04/07/2005 | WO2005030975A1 METHOD OF PREPARING α-GLYCOSYLISOQUERCITRIN, INTERMEDIATE THEREFOR, AND BY-PRODUCT |
| 04/07/2005 | WO2005030960A1 Staple type oligonucleotide and drug comprising the same |
| 04/07/2005 | WO2005030955A1 Protein expressed in nk cell |
| 04/07/2005 | WO2005030953A1 Tetrahydrofolate synthase gene |
| 04/07/2005 | WO2005030796A1 Macrocyclic inhibitors of hepatitis c virus ns3 serine protease |
| 04/07/2005 | WO2005030794A2 Hemiasterlin derivatives and uses thereof |
| 04/07/2005 | WO2005030792A2 Quinoline potassium channel inhibitors |
| 04/07/2005 | WO2005030791A2 Isoquinolinone potassium channel inhibitors |
| 04/07/2005 | WO2005030790A1 Novel triterpene derivatives, preparation thereof and use thereof |
| 04/07/2005 | WO2005030786A1 3'-n-substituted-3-o-substituted erythronolide a derivatives |
| 04/07/2005 | WO2005030778A1 Ligands |
| 04/07/2005 | WO2005030777A1 Non-amide nonanes |
| 04/07/2005 | WO2005030776A1 Pyrazolopyrrole derivatives as protein kinase inhibitors |
| 04/07/2005 | WO2005030774A1 Hcv inhibitors and methods of using them |
| 04/07/2005 | WO2005030767A1 Novel macrocycles for treating tumor diseases |
| 04/07/2005 | WO2005030765A1 Quinazoline derivatives as antiproliferative agents |
| 04/07/2005 | WO2005030763A1 Benzisoxazoles |
| 04/07/2005 | WO2005030762A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 04/07/2005 | WO2005030761A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 04/07/2005 | WO2005030760A1 Substituted heteroaryl benzofuran acids |
| 04/07/2005 | WO2005030758A1 Pyrimidine and pyridine derivatives useful as hmg-coa reductase inhibitors and method of preparation thereof |
| 04/07/2005 | WO2005030757A1 Quinazoline derivatives |
| 04/07/2005 | WO2005030754A1 Indole or quinoline derivatives as non-pepticid npy y2 receptor inhibitors useful for the treatment of anxiolytic and depressive disorders and obesity |
| 04/07/2005 | WO2005030753A2 Therapeutic agents useful for treating pain |
| 04/07/2005 | WO2005030752A1 8-cyanoquinolonecarboxylic acid derivative |
| 04/07/2005 | WO2005030751A2 Dipeptidyl peptidase inhibitors |
| 04/07/2005 | WO2005030749A1 Calcilytic compounds |
| 04/07/2005 | WO2005030737A1 Phenylene derivative having tetrazole ring or thiazolidinedione ring |
| 04/07/2005 | WO2005030735A1 Triazines derivatives as cell adhesion inhibitors |
| 04/07/2005 | WO2005030734A1 Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (ghs-r) antagonists |
| 04/07/2005 | WO2005030733A1 Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof |
| 04/07/2005 | WO2005030732A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 04/07/2005 | WO2005030717A1 Substituted indole acid derivatives and their use as pai-1 inhibitors |
| 04/07/2005 | WO2005030716A1 Heterocyclic- or aryloxy, -thio or -amino substituted indoles-2-carboxylic acids or esters as pai-1 |
| 04/07/2005 | WO2005030698A1 Process for the preparation of voglibose |
| 04/07/2005 | WO2005030678A2 AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS |
| 04/07/2005 | WO2005030333A2 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2] [2]- benzazepine, method for the production thereof and use thereof in the production of medicaments |
| 04/07/2005 | WO2005030332A2 Use of galanthamine and the derivatives thereof in the production of medicaments |
| 04/07/2005 | WO2005030331A1 Combination antihistamine medication |
| 04/07/2005 | WO2005030329A1 Method of damaging biomolecule and biomolecule damaging apparatus |
| 04/07/2005 | WO2005030263A1 Use of gas for the manufacture of a monitoring agent for diagnostic passage through the intestinal tract or exocrine function of the pancreas |
| 04/07/2005 | WO2005030262A1 Use of a gas for the manufacture of a diagnosing agent for diagnosing coronary perfusion |
| 04/07/2005 | WO2005030260A1 Bispecific oligonucleotide for the treatment of cns malignancies |
| 04/07/2005 | WO2005030258A2 Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| 04/07/2005 | WO2005030239A2 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
| 04/07/2005 | WO2005030233A1 Active oxygen scavenging agent and process for producing the same |
| 04/07/2005 | WO2005030228A2 Use of a composition containing extracts of vitis vinifera and lycopersicum for protecting the skin |
| 04/07/2005 | WO2005030227A1 9a, 11-3C-BICYCLIC 9a-AZALIDE DERIVATIVES |
| 04/07/2005 | WO2005030226A1 Compositions and methods of using lamellar bodies for therapeutic purposes |
| 04/07/2005 | WO2005030225A2 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers |
| 04/07/2005 | WO2005030224A1 Nitrosylated analgesic and/or anti-inflammatory drugs having antiviral activity |
| 04/07/2005 | WO2005030223A1 Methods for treating bladder dysfunction |
| 04/07/2005 | WO2005030222A1 1,3-diaclyated,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof |
| 04/07/2005 | WO2005030221A1 Therapeutic agent for ageing macular degeneration |
| 04/07/2005 | WO2005030220A1 Pulmonary disease treatment |
| 04/07/2005 | WO2005030219A1 Method of stabilizing diarylvinylene compound |
| 04/07/2005 | WO2005030218A1 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agent |
| 04/07/2005 | WO2005030216A1 5-arylpyrimidines as anticancer agents |
| 04/07/2005 | WO2005030215A2 Therapeutic treatment |
| 04/07/2005 | WO2005030213A1 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo |
| 04/07/2005 | WO2005030212A1 4-aminoquinoline-3-carboxamide derivatives as pde4 inhibitors |
| 04/07/2005 | WO2005030211A1 Aerosol formulation for inhalation, containing an anticholinergic agent |
| 04/07/2005 | WO2005030210A1 Treatment of neurological disorders related to rapid eye movement (rem) sleep disturbances with npy y5 receptor antagonists |
| 04/07/2005 | WO2005030209A1 Pyridine derivatives and use thereof as urotensin ii antagonists |
| 04/07/2005 | WO2005030208A1 Use of npy y5 receptor antagonist for the treatment of circadian rhythm disorders |
| 04/07/2005 | WO2005030207A1 Use of 3, 7-diazabicyclo (3.3.1) nonane compounds for the treatment of brugada syndrome |
| 04/07/2005 | WO2005030206A1 Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity |
| 04/07/2005 | WO2005030205A1 Ocular solutions containing a macrolide antibiotic and/or mycophenolic acid |
| 04/07/2005 | WO2005030204A1 Substituted oxadiazolidinediones as pai-1 inhibitors |
| 04/07/2005 | WO2005030202A1 Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders |
| 04/07/2005 | WO2005030201A1 Sustained release preparation containing hydrochlorothiazide |
| 04/07/2005 | WO2005030200A1 Remedy for autoimmune diseases |
| 04/07/2005 | WO2005030198A1 Medicinal composition for treatment for fatty liver or liver disease |
| 04/07/2005 | WO2005030197A1 Compound artemisinin |
| 04/07/2005 | WO2005030195A1 (-)-hydroxycitric acid for delaying gastric emptying |
| 04/07/2005 | WO2005030194A1 Hcv inhibitiing sulfonamides |
| 04/07/2005 | WO2005030193A1 4-(phenyl-ethylideneaminoxy-propoxy) -phenyl-acetic acid derivatives and related compounds as pai-1 inhibitors for the treatment of impairment of the fibrinolytic system and of thrombosis |
| 04/07/2005 | WO2005030192A1 4- (1h-indol-3-yl-methylideneaminoxy-propoxy) -benzioc acid derivatives and related compounds as pai-1 inhibitors for the treatment of impairment of the fibrinolytic system and of thrombisis |
| 04/07/2005 | WO2005030190A1 Natural menaquinone 7 compositions |
| 04/07/2005 | WO2005030189A1 Novel therapeutic use of 4-hydroxybenzyl alcohol, 4-hydroxybenzyl aldehyde and vanillin |
| 04/07/2005 | WO2005030188A2 Phenyl-piperazine derivatives as modulators of muscarinic receptors |
| 04/07/2005 | WO2005030187A2 Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| 04/07/2005 | WO2005030186A2 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation |
| 04/07/2005 | WO2005030185A2 Method of inhibiting remnant lipoprotein production |
| 04/07/2005 | WO2005030184A2 Therapeutic beta aminoacids |
| 04/07/2005 | WO2005030183A2 A method for the preparation of atorvastatin calcium tablets |
| 04/07/2005 | WO2005030182A1 Controlled release formulations exhibiting an ascending rate of release |
| 04/07/2005 | WO2005030181A1 Controlled release formulations of opioid and nonopioid analgesics |
| 04/07/2005 | WO2005030180A1 Osmotic dosage forms for controlled delivery of alprazolam |
| 04/07/2005 | WO2005030178A1 Extended release formulation of beta-lactam antibiotics |
| 04/07/2005 | WO2005030177A2 Pharmaceutical formulation with improved stability |
| 04/07/2005 | WO2005030176A1 Improved stability of progestogen formulations |
| 04/07/2005 | WO2005030175A1 Hrt formulations |
| 04/07/2005 | WO2005030173A1 Colon-specific drug delivery using interpolymer complexations |
| 04/07/2005 | WO2005030171A1 Delivery of therapeutic compounds via microparticles or microbubbles |
| 04/07/2005 | WO2005030167A2 Buccal, polar and non-polar spray containing alprazolam |
| 04/07/2005 | WO2005030166A1 Oros push-stick for controlled delivery of active agents |